Astria Therapeutics, Inc. (ATXS) Stock
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Astria Therapeutics, Inc. is headquartered in US.
Astria Therapeutics, Inc. (ATXS) stock trades at $12.58 with a market capitalization of $718.13M. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.40, reflecting a net loss over the last twelve months, price-to-book of 3.13, price-to-sales of 1017.18. Over the past 52 weeks the stock has ranged between $3.56 and $13.29, and currently trades 5.3% below its 52-week high.
On profitability, Astria Therapeutics, Inc. generates a return on equity (ROE) of -37.70% (negative, reflecting a net loss), return on capital employed of -43.05%.
Official website: www.astriatx.com
Astria Therapeutics, Inc. by the numbers, 2015–2024
Between 2015 and 2024 Astria Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-94.0M.
On a trailing twelve-month basis to Sep '25, revenue is $1.0M and net profit $-125.0M.
Borrowings fell from $9.0M to $5.0M, cash on hand is $227.7M, cash from operations was $-81.0M in the latest year, positive in 0 of the last 10.
Return on equity has averaged -66.6% over five years, and was -29.5% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Astria Therapeutics, Inc. (ATXS) — frequently asked questions
What is Astria Therapeutics, Inc. (ATXS) stock price today?
Astria Therapeutics, Inc. (ATXS) is currently trading at $12.58, up 0% today.
What is ATXS P/E ratio?
Astria Therapeutics, Inc.'s P/E ratio is -7.40. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is ATXS return on equity (ROE)?
Astria Therapeutics, Inc.'s return on equity (ROE) is -37.70%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Astria Therapeutics, Inc.'s market cap?
Astria Therapeutics, Inc. has a market capitalization of $718.13M.
Does ATXS pay a dividend?
Astria Therapeutics, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does ATXS carry?
Astria Therapeutics, Inc. has a debt-to-equity ratio of 0.02. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What sector is ATXS in?
Astria Therapeutics, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is ATXS listed on?
Astria Therapeutics, Inc. trades on NASDAQ under the ticker ATXS.
What is ATXS's 52-week range?
Over the last year Astria Therapeutics, Inc. has traded between $3.56 and $13.29.
Related Healthcare Stocks
Popular Stocks
Screens ATXS currently matches
On the figures above, Astria Therapeutics, Inc. passes the filters for 8 of our ready-made screens, among them Small Cap Stocks, Debt Free Stocks Under $100, Debt Free Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.